1. Home
  2. ETRA

as of 11-20-2026 3:59pm EST

$8.14
$0.77
-8.64%
Stocks Nasdaq

Electra Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's pipeline includes Ipsoprubart and ELA822.

Founded: 2018 Country:
United States
United States
Employees: N/A City: N/A
Market Cap: 593.1M IPO Year: 2026
Target Price: $33.20 AVG Volume (30 days): 315.5K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -35.24 EPS Growth: N/A
52 Week Low/High: $6.87 - $15.14 Next Earning Date: 11-12-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: -0.25 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Stock Insider Trading Activity of Electra Therapeutics Inc. Common stock (ETRA)

ORBIMED ADVISORS LLC

Director, 10% Owner

Buy
ETRA Nov 10, 2026

Avg Cost/Share

$8.45

Shares

22,700

Total Value

$191,815.00

Owned After

2,194,579

GORDON CARL L

Director, 10% Owner

Buy
ETRA Nov 10, 2026

Avg Cost/Share

$8.45

Shares

22,700

Total Value

$191,815.00

Owned After

5,255,278

ORBIMED ADVISORS LLC

Director, 10% Owner

Buy
ETRA Nov 9, 2026

Avg Cost/Share

$8.24

Shares

20,000

Total Value

$164,800.00

Owned After

2,194,579

GORDON CARL L

Director, 10% Owner

Buy
ETRA Nov 9, 2026

Avg Cost/Share

$8.24

Shares

20,000

Total Value

$164,800.00

Owned After

5,255,278

ORBIMED ADVISORS LLC

Director, 10% Owner

Buy
ETRA Nov 6, 2026

Avg Cost/Share

$7.85

Shares

49,416

Total Value

$387,915.60

Owned After

2,194,579

GORDON CARL L

Director, 10% Owner

Buy
ETRA Nov 6, 2026

Avg Cost/Share

$7.85

Shares

49,416

Total Value

$387,915.60

Owned After

5,255,278

ORBIMED ADVISORS LLC

Director, 10% Owner

Buy
ETRA Nov 5, 2026

Avg Cost/Share

$7.31

Shares

156,091

Total Value

$1,141,025.21

Owned After

2,194,579

GORDON CARL L

Director, 10% Owner

Buy
ETRA Nov 5, 2026

Avg Cost/Share

$7.31

Shares

156,091

Total Value

$1,141,025.21

Owned After

5,255,278

ORBIMED ADVISORS LLC

Director, 10% Owner

Buy
ETRA Nov 4, 2026

Avg Cost/Share

$7.43

Shares

71,367

Total Value

$537,485.26

Owned After

2,194,579

SEC Form 4

GORDON CARL L

Director, 10% Owner

Buy
ETRA Nov 4, 2026

Avg Cost/Share

$7.43

Shares

71,367

Total Value

$537,485.26

Owned After

5,255,278

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K

Nov 12, 2026

0001193125-26-458464

EX-99.1

2 etra-ex99_1.htm

EX-99.1

EX-99.1

Electra Therapeutics Reports Third Quarter 2026 Financial Results and Recent Portfolio Highlights

Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027

Ipsoprubart Therapeutic Expansion Underway in Phase 1 Trial for T/NK Cell Malignancies, with Initial Data Expected in the Second Half of 2027

ELA822 Healthy Volunteer Data Expected in the First Half of 2027, with Patient Trial Initiation Planned for Mid-2027

Completed $350 Million IPO to Fund Advancement of SIRP-Targeting Portfolio

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2026 -- Electra Therapeutics, Inc. (Nasdaq: ETRA), a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today reported financial results for the third quarter ended September 30, 2026 and provided an overview of its portfolio and recent business highlights.

“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion,” said Kathy Dong, PharmD, MBA, President and Chief Executive Officer of Electra Therapeutics. “Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer. Building on compelling clinical data in sHLH, we are advancing ipsoprubart through a global registrational program and evaluating its potential in T/NK cell malignancies. With ELA822 now in Phase 1, we are advancing multiple programs with the potential to benefit patients and create value for our stakeholders. We anticipate several important milestones in 2027, including ELA822 healthy volunteer data expected in the first half of the year, followed by ipsoprubart data in T/NK cell malignancies and completion of enrollment in the sHLH registrational program in the second half.”

Electra’s novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression increases upon activation in specific immune cell populations. This approach is designed to selectively deplete disease-driving immune cells while preserving normal immune function. By offering a more targeted alternative to broad immunosuppression, this approach has the potential to bring greater precision to the treatment for immune-mediated diseases, much as precision oncology has transformed cancer care.

Portfolio Overview

• Ipsoprubart Global Registrational Development for sHLH: The company’s lead product candidate, ipsoprubart, is a novel pan-SIRP monoclonal antibody in development for secondary hemophagocytic lymphohistiocytosis (sHLH), designed to selectively deplete the pathogenic SIRPα/b1-positive myeloid cells and SIRPg-positive T cells characteristic of sHLH.

o In a Phase 1b trial, ipsoprubart was generally well tolerated and demonstrated 100% overall survival at eight weeks and a 100% overall response rate at the week four assessment in 12 frontline patients with malignancy-associated HLH, the largest subset of sHLH and the population with the poorest outcomes.

o The company’s global registrational program comprises SURPASS, a Phase 2/3 trial in newly diagnosed, treatment-naïve sHLH patients, and COMPASS, a retrospective natural history study designed to provide an external control comparator, with enrollment completion expected in the second half of 2027.

• ASH Abstract Acceptances: Two abstracts, including an analysis of healthcare claims data and preclinical data on SIRPα/β1/γ expression in pathogenic immune cells, have been accepted for poster presentations at the 2026 American Society of Hematology Annual Meeting (ASH) on December 13, 2026, from 6:00–8:00 p.m. CT. Presentation details are as follows:

o Title: Increasing burden of secondary hemophagocytic lymphohistiocytosis in the United States: A national-claims analysis of associated conditions, treatments, and care patterns, 2016-2025

▪ Abstract number: 4454

▪ Session: 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster II

o Title: SIRPα/β1/γ expression is enriched on pathogenic immune cell populations in adults with secondary hemophagocytic lymphohistiocytosis

▪ Abstract number: 2965

▪ Session: 201. Granulocytes, Monocytes, and Macrophages: Poster II

• Ipsoprubart for T Cell Malignancies: Ipsoprubart is also being evaluated as single-agent therapy in patients with relapsed/refractory T/NK cell malignancies.

o Among eight sHLH patients with underlying T- or B-cell lymphomas and available objective tumor response assessments across the Phase 1b trial and Expanded Access Program, all eight patients had an objective tumor response and seven had complete responses.

o Based on this anti-tumor activity, the company is conducting

Share on Social Networks: